Form D · Biotechnology
Provista Diagnostics Inc.
Scottsdale, AZ · CIK 0001539252
Offering snapshot reported May 22, 2018 · SEC filing
- Reported sold
- $2.21M Offering amount: $5M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 17, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 22, 2018 | Initial | $2,205,633 | No comparison | 6 | SEC filing |
| Sep 15, 2017 | Initial | $2,331,084 | No comparison | 28 | SEC filing |
| Oct 26, 2016 | Initial | $2,564,948 | No comparison | 5 | SEC filing |
| Mar 18, 2016 | Initial | $5,100,990 | No comparison | 25 | SEC filing |
| Aug 3, 2015 | Initial | $6,046,254 | No comparison | 27 | SEC filing |
| Mar 16, 2015 | Initial | $3,870,986 | No comparison | 24 | SEC filing |
| Apr 17, 2014 | Initial | $6,000,000 | No comparison | 34 | SEC filing |
| Apr 24, 2013 | Initial | $5,999,999 | No comparison | 35 | SEC filing |
| Sep 21, 2012 | Amendment | $7,485,891 | $2,975,891vs Mar 1, 2012 | 32 | SEC filing |
| Mar 1, 2012 | Initial | $4,510,000 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-312969
The Issuer is offering up to $5,000,000 in principal amount of convertible notes. This Form D is also intended to cover the underlying equity securities. A portion of the total amount sold was funded by cancellation of indebtedness and a note exchange.
Source: Form D, filed May 22, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gary Altman | Director, Executive |
| Anne Busquet | Director |
| Cynthia Collins | Director |
| John Fermanis | Executive |
| William Gartner | Executive |
| Jeffrey R. Gilman | Director |
| Robert J. Hariri | Director |
| Uriel E. Kusiatin | Executive |
| Jack Levine | Director |
| John Macaskill | Director |
| Thomas G. Mendell | Director |
| Rao Mulpuri | Executive |
| Yoji Nimura | Director |
| David Reese | Director, Executive |
| John Zicarelli | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
17301 N. Perimeter Drive, Suite 100
Scottsdale, AZ, 85255
Scottsdale, AZ, 85255